8-K: Longevity Health Holdings Announces Merger Agreement with 20/20 BioLabs and Reports Preliminary Q1 2025 Sales

Longevity Health Holdings reports preliminary Q1 2025 sales increase, finalizes merger agreement with 20/20 BioLabs, and plans new product launches and additional financing.

Summary

• Longevity Health Holdings (XAGE) announced a merger agreement with 20/20 BioLabs, with 20/20 expected to become a wholly-owned subsidiary of XAGE.
• The company filed an S-4 prospectus with the SEC on May 8, 2025, regarding the merger.
• Preliminary unaudited Q1 2025 sales for XAGE were approximately $663,000 on a pro forma basis, an 8% increase year-over-year.
• 20/20 BioLabs reported preliminary Q1 2025 sales of approximately $562,000, a 15% increase year-over-year.
• XAGE completed a 1-for-30 reverse stock split on May 12, 2025, and the stock began trading at the adjusted price on May 14, 2025.
• XAGE expects to launch a medicated cleanser in Q2 2025, targeting physicians' offices, MedSpas, and 20/20's customer base.
• 20/20 BioLabs plans to launch a new lab test measuring inflammatory biomarkers in the blood, also in Q2 2025, and will market it to XAGE's customer base.
• 20/20 announced an initiative with Giant Food to offer its multi-cancer test in 9 stores in Maryland and Virginia.
• XAGE is evaluating options for additional financing and anticipates announcing a primary investment in Q2 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's growth and a merger, there are also risks related to financing and regulatory approvals. The reverse stock split is generally viewed negatively.

Positives

• Both Longevity Health Holdings and 20/20 BioLabs experienced sales growth in Q1 2025.
• The merger agreement with 20/20 BioLabs is finalized, potentially creating synergies and expanding market reach.
• New product launches are planned for Q2 2025, which could drive further revenue growth.
• The initiative with Giant Food could expand 20/20's market presence and accessibility.
• The company is actively seeking additional financing, which could support future growth initiatives.

Negatives

• The financial results are preliminary and unaudited, subject to revision.
• The company is dependent on the successful closing of the merger with 20/20.
• The company is dependent on securing additional financing.
• The company is dependent on successful product launches.

Risks

• The merger with 20/20 BioLabs is subject to various closing conditions, including stockholder approval and regulatory approvals.
• Failure to maintain Nasdaq Capital Market listing could negatively impact the company.
• The company may not be able to obtain sufficient additional capital to advance commercialization and marketing efforts.
• The company may not realize the anticipated benefits of the proposed merger.
• The concurrent financing may not be consummated prior to the closing of the merger.
• The company is subject to risks described in its Annual Report on Form 10-K filed with the SEC on March 31, 2025.

Future Outlook

The company anticipates new product launches in Q2 2025 and is evaluating options for additional financing. The merger with 20/20 BioLabs is expected to close, subject to customary conditions.

Industry Context

The announcement reflects a trend in the healthcare industry towards consolidation and expansion of diagnostic and regenerative medicine offerings. The merger with 20/20 BioLabs aligns with the broader industry focus on early disease detection and proactive health management.

Comparison to Industry Standards

• Comparing XAGE's growth to companies like NovaBay Pharmaceuticals, Inc. (NBY) in the skincare sector, the 8% sales increase is moderate.
• 20/20's 15% growth is comparable to companies like Exact Sciences (EXAS) in the early cancer detection space, but on a much smaller revenue base.
• The merger strategy mirrors moves by companies like NeoGenomics (NEO) acquiring smaller diagnostic firms to expand their test portfolios.

Stakeholder Impact

• Shareholders will be impacted by the merger, reverse stock split, and potential financing.
• Employees of both companies may experience changes due to the merger.
• Customers may benefit from new products and expanded offerings.
• The company's financial stability could impact suppliers and creditors.

Next Steps

• Obtain stockholder approval for the merger.
• Secure necessary regulatory approvals for the merger.
• Finalize and announce additional financing.
• Launch new products in Q2 2025.
• Close the merger with 20/20 BioLabs.

Key Dates

Keywords

Merger, 20/20 BioLabs, Longevity Health Holdings, XAGE, Sales, Q1 2025, Reverse Stock Split, Product Launch, Financing, Diagnostics, Bio-aesthetics, Nutrition